An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)

Trial Profile

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 May 2017

At a glance

  • Drugs Inotersen (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 07 Jul 2016 New data from this trial were presented at the XV International Symposium on Amyloidosis (ISA), according to an Ionis Pharmaceuticals media release.
    • 23 Mar 2016 Planned number of patients changed from 195 to 172, as reported by ClinicalTrials.gov.
    • 23 Mar 2016 Planned End Date changed from 1 Dec 2018 to 1 Aug 2020, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top